Authors
Loading...
Key points are not available for this paper at this time.
The head-to-head SURMOUNT-5 trial demonstrated that tirzepatide resulted in superior weight loss compared to semaglutide in adults with obesity, a highly anticipated result with major implications for obesity and cardiometabolic medicine.
Aronne et al. (2025) studied this question.